US gives conditional nod to Zoetis' bird flu vaccine for poultry

Reuters
02-15
UPDATE 3-US gives conditional nod to Zoetis' bird flu vaccine for poultry

Adds details on the Wyoming case in paragraph 3

Feb 14 (Reuters) - The U.S. Department of Agriculture has given a conditional approval to Zoetis ZTS.N to use its bird flu vaccine in poultry, the animal healthcare company said on Friday.

Bird flu has infected nearly 70 people in the United States, with one death, since last April. Most of those infections have been among farm workers exposed to infected poultry or cows.

The Wyoming Department of Health said on Friday it has identified its first human case of H5N1 bird flu in the region, making it the third confirmed instance of hospitalization related to the infection in the United States.

The U.S. Centers for Disease Control and Prevention, however, has said the risk to the general public from bird flu is low.

Zoetis, which deals with vaccines, medicines as well as diagnostic solutions for animals, said the conditional license was granted based on safety and reasonable expectation of efficacy.

A conditional approval, called a conditional license, is used for emergencies, limited market availability, or other special circumstance and is issued for a finite period of time.

Last month, USDA said it would rebuild a stockpile of bird flu vaccines for poultry that match the strain of the virus circulating in commercial flocks and wild birds.

The U.S. had built a poultry vaccine stockpile after major bird flu outbreaks in 2014 and 2015, though they were never used.

The vaccines were developed by Merck MRK.N, Ceva CEVA.O and one by U.S. government researchers, David Suarez, who was acting laboratory director of USDA's Southeast Poultry Research Laboratory in Athens, Georgia, had said in a 2023 interview.

Separately, Moderna MRNA.O is developing a bird flu vaccine for humans and has received about $766 million from the U.S. government for its advancement.

The company said last month it was preparing to advance its experimental shot, mRNA-1018, into late-stage trials based on preliminary data from an early- to mid-stage study.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)

((Christy.Santhosh@thomsonreuters.com))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10